Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2022

View Archived Issues

BBT-207, a fourth-generation EGFR TKI with activity against most common mutants

Bristol Myers Squibb describes new FPR1/2 agonists

New KCNA3 channel blockers identified at DE Shaw Research

Vertex Pharmaceuticals discovers CFTR modulators

Curome Biosciences presents new quinone derivatives

New mucolipin-1 activators identified at Lysoway Therapeutics

Innate immune memory underlies inflammatory comorbidities: study

CF-370 shows synergy with amikacin in drug-resistant P. aeruginosa acute pneumonia model

BioNova Pharmaceuticals menin inhibitor BNM-1192 shows promise for MLL rearranged leukemias

Bridge Biotherapeutics and Cyrus Therapeutics generate next-generation EGFR degraders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 10, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026